Abstract 2414: A phase I/II clinical trial to evaluate the efficacy of combined epigenetic therapy for improving temozolomide chemosensitivity in metastatic melanoma

Abstract

Peer reviewed

Chang Xia, Jeremy M. Deutsch, Mohammed M. Milhem, Brian J. Smith, Douglus Laux and Raymond Hohl

Cancer research (Chicago, Ill.), Vol.73(8 Supplement), pp.2414-2414

04/15/2013

DOI: 10.1158/1538-7445.AM2013-2414

View Online

Title: Subtitle: Abstract 2414: A phase I/II clinical trial to evaluate the efficacy of combined epigenetic therapy for improving temozolomide chemosensitivity in metastatic melanoma
Creators: Chang Xia - 1UIHC, Iowa City, IA;
Jeremy M. Deutsch - 1UIHC, Iowa City, IA;
Mohammed M. Milhem - 1UIHC, Iowa City, IA;
Brian J. Smith - 1UIHC, Iowa City, IA;
Douglus Laux - 2Jefferson City Medical Group, Jefferson City, MO.
Raymond Hohl - 1UIHC, Iowa City, IA;
Resource Type: Abstract
Publication Details: Cancer research (Chicago, Ill.), Vol.73(8 Supplement), pp.2414-2414
DOI: 10.1158/1538-7445.AM2013-2414
ISSN: 0008-5472
eISSN: 1538-7445
Language: English
Date published: 04/15/2013
Academic Unit: Biostatistics; Holden Comprehensive Cancer Center; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984226815602771

5 Record Views